Concepedia

Dennis Kannenkeril

DK

Statistics

Publications

26

Citations

1.5K

H-Index

17

Active since

2009

Affiliations

Friedrich-Alexander-Universität Erlangen-Nürnberg(Current)

Universitätsklinikum Erlangen

Paracelsus Medizinische Privatuniversität

IPPMed (Germany)

Saarland University

Dennis Kannenkeril is an author at Friedrich-Alexander-Universität Erlangen-Nürnberg specializing in medicine, neuropathology, and neurology.

ORCID

Top concepts

Publications per year

2009–2023

26

Publications

26

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

Michael Böhm, Kazuomi Kario, David E. Kandzari et al. · The Lancet · 2020 · 555 citations

, , +9

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Marina V. Karg, Agnes Bosch, Dennis Kannenkeril et al. · Cardiovascular Diabetology · 2018 · 180 citations · Full text

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Agnes Bosch, Christian Ott, Susanne Jung et al. · Cardiovascular Diabetology · 2019 · 109 citations · Full text

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications

David E. Kandzari, Raymond R. Townsend, Kazuomi Kario et al. · Journal of the American College of Cardiology · 2023 · 93 citations

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure

Robert Pietschner, Julie Kolwelter, Agnes Bosch et al. · Cardiovascular Diabetology · 2021 · 64 citations · Full text

1–5 of 26